Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DTYMK | P23919 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499618 | 0.77 | MEN1 (0.58) | MEN1KMT2ADTYMKCYP1A2CYP2C19 | |
| SCHEMBL1717207 | 0.76 | MEN1 (0.78) | MEN1KMT2ADTYMKGRIA1GRIA2 | |
| SCHEMBL12501025 | 0.75 | MEN1 (0.50) | MEN1KMT2ADTYMK | |
| SCHEMBL8022167 | 0.74 | MEN1 (0.66) | MEN1KMT2ADTYMKALDH1A1HPGD | |
| SCHEMBL12501006 | 0.74 | KMT2A (0.66) | MEN1KMT2ADTYMKGRIA1GRIA2 | |
| SCHEMBL13992284 | 0.73 | GRIA1 (0.53) | MEN1KMT2ADTYMKGRIA1GRIA2 | |
| SCHEMBL7840035 | 0.72 | MEN1 (0.71) | MEN1KMT2ADTYMKCYP1A2CYP2C19 | |
| SCHEMBL125267 | 0.70 | MEN1 (0.53) | MEN1KMT2ADTYMKGRIA1GRIA2 | |
| SCHEMBL14208526 | 0.70 | DTYMK (0.91) | MEN1KMT2ADTYMK | |
| SCHEMBL14208557 | 0.70 | DTYMK (0.74) | MEN1KMT2ADTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | MEN1 2207/4885KMT2A 3185/4885DTYMK 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.